Effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy

doi:10.3760/cma.j.issn.1673-422X.2018.03.008

Abstract

Abstract: Objective To investigate the effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy. MethodsOne hundred and thirtyeight patients with advanced gastric cancer were enrolled in our hospital from October 2014 to December 2016, and were randomly divided into control group (n=69) and observation group (n=69) by using the random number table. The patients of the control group were treated with FOLFOX4 chemotherapy (oxaliplatin + calcium folinate + fluorouracil), while the patients of the observation group were given by the treatment of Dingkoulizhong decoction on the basis of the control group. The peripheral blood samples of the patients were collected before and after the treatment. The levels of cellular immune factors CD3+, CD4+, CD8+ and CD4+/CD8+ were detected, and the clinical efficacy and adverse reactions of the patients of the two groups were observed. Results After the treatment, the number of complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD) in the observation group were 16, 25, 16 and 12 cases respectively, while the control group were 9, 20, 19 and 21 cases respectively, and there was a statistically significant difference in the distribution of clinical efficacy between the two groups (Z=4.381, P=0.036). Compared with the control group, the clinical benefit rate (CBR) of the observation group was significantly improved (59.42% vs. 42.03%), with a statistically significant difference (χ2=4.175, P=0.041). The cellular immune factors CD3+［(52.67±6.21)% vs. (53.45±6.54)%］, CD4+［(23.56±3.85)% vs. (24.09±2.91)%］, CD8+［(28.16±3.49)% vs. (27.87±3.26)%］ and CD4+/CD8+ (1.13±0.27 vs. 1.19±0.31) of the patients of the observation group showed no statistically significant difference (t=0.718, P=0.474; t=0.912, P=0.363; t=0.504, P=0.615; t=1.212, P=0.227) before and after the treatment, but the cellular immune factor CD3+［(50.36±3.74)% vs. (53.13±6.12)%］, CD4+［(21.26±2.37)% vs. (23.44±3.96)%］ and CD4+/CD8+ (0.96±0.26 vs. 1.15±0.25) of the patients of the control group after the treatment were significantly lower than those before the treatment, and CD8+［(31.64±4.05)% vs. (27.98±3.52)%］ after the treatment was significantly higher than that before the treatment, all with statistically significant differences (t=3.208, P＜0.001; t=3.924, P＜0.001; t=4.289 P＜0.001, t=5.666, P＜0.001). Compared with the control group, the level of CD3+［(53.45±6.54)% vs. (50.36±3.74)%］, CD4+［(24.09±2.91)% vs. (21.26±2.37)%］ and CD4+/CD8+ (1.19±0.31 vs. 0.96±0.26) of the patients of the observation group after the treatment were significantly improved, and CD8+［(27.87±3.26)% vs. (31.64±4.05)%］ was significantly decreased, all with statistically significant differences (t=3.407, P=0.001; t=6.264, P＜0.001; t=4.722, P＜0.001; t=6.023, P＜0.001). Compared with the control group, the total adverse reaction rate of the observation group was significantly decreased (36.23% vs. 55.07%), with a statistically significant difference (χ2=4.936, P=0.026). Conclusion Dingkoulizhong decoction can significantly improve the clinical efficacy in patients with advanced gastric cancer treated with chemotherapy, alleviate the immune function damage caused by chemotherapy, and it can reduce the occurrence of adverse reactions.

Key words: Stomach neoplasms, Drug therapy, Cytokines, Dingkoulizhong decoction

Yang Aiwu, Lin Zhimin, Zhang Jiangling, Liang Renpei, Zheng Weibin. Effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy[J]. Journal of International Oncology, 2018, 45(3): 161-165.

References

［1］马易, 李雨欣, 孙哲. 化疗联合DCCIK治疗晚期胃癌疗效及对免疫功能的影响［J］. 现代中西医结合杂志, 2016, 25(21): 2303-2305. DOI: 10.3969/j.issn.1008-8849.2016.21.007. ［2］ Barbosa OA, de Souza ADB, Moura MRC, et al. Diffuse gastric cancer during pregnancy: report of a rare association.［J］. World J Oncol, 2015, 6(5): 456-458. DOI: 10.14740/wjon945w. ［3］郭运来, 全晓红. 参芪扶正注射液在进展期胃癌化疗过程中对患者免疫功能的影响［J］. 世界中医药, 2015, 10(6): 859861. DOI: 10.3969/j.issn.16737202.2015.06.014. ［4］陈灏珠, 钟南山, 陆再英. 内科学: 第8版［M］. 人民卫生出版社, 2013: 385-388. ［5］周际昌. 实用肿瘤内科学: 第2版［M］. 人民卫生出版社, 2005: 4748. ［6］李晓利, 牛敏, 张铭, 等. 香菇多糖注射液联合化疗对晚期胃癌患者免疫功能和临床疗效的影响［J］. 陕西医学杂志, 2015, 44(12): 1624-1626. DOI: 10.3969/j.issn.1000-7377.2015.12.027. ［7］ Bagheri N, AzadeganDehkordi F, Rahimian G, et al. Role of regulatory Tcells in different clinical expressions of Helicobacter pylori infection［J］. Arch Med Res, 2016, 47(4): 245-254. DOI: 10.1016/j.arcmed.2016.07.013. ［8］周子仪. DCCIK免疫治疗联合常规化疗对晚期胃癌患者血清学及外周血免疫功能指标的影响［J］. 海南医学院学报, 2015, 21(7): 981-983, 987. DOI: 10.13210/j.cnki.jhmu.20150226.019. ［9］ Kalamohan K, Rathinam D, Panneerpandian P, et al. Coexpressed modular gene expression reveals inverse correlation between immune responsive transcription and aggressiveness in gastric tumours［J］. Cancer Immunol Immunother, 2017, 66(7): 941954. DOI: 10.1007/s0026201719987. ［10］宁四清, 徐海声, 杨超. 复方苦参注射液联合FOLFOX4化疗方案治疗晚期胃癌的临床研究［J］. 现代药物与临床, 2015, 30(3): 275-278. DOI: 10.7501/j.issn.1674-5515.2015.03.010. ［11］胡培. 参芪扶正注射液对进展期胃癌化疗患者免疫功能的影响［J］. 现代中西医结合杂志, 2017, 26(3): 292294. DOI: 10.3969/j.issn.10088849.2017.03.022. ［12］邵扣凤, 肖平. 参苓白术散加减方对晚期胃癌化疗患者毒副反应及免疫功能的影响［J］. 中医药导报, 2016, 22(8): 26-28, 32. DOI: 10.13862/j.cnki.cn43-1446/r.2016.08.008. ［13］段永强, 程卫东, 成映霞, 等. 四君子汤和理中汤干预腹泻型IBS大鼠胃肠转运功能和P物质、胆囊收缩素的比较研究［J］. 中成药, 2015, 37(2): 405-408. DOI: 10.3969/j.issn.1001-1528.2015.02.039. ［14］郑晓川. 理中汤合六君子汤加减治疗胃癌术后胃肠功能障碍疗效观察［J］. 现代中西医结合杂志, 2015, 24(33): 3690-3692. DOI: 10.3969/j.issn.1008-8849.2015.33.015. ［15］杜联江, 柳言平. 丁蔻理中汤联合化疗治疗晚期胃癌疗效观察［J］. 陕西中医, 2015, 36(5): 518-519. DOI: 10.3969/j.issn.10007369.2015.05.002.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[4]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[5]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[6]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[9]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[10]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[13]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[14]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[15]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.